Fact-checked by Grok 2 weeks ago

Bcl-2

Bcl-2, or B-cell lymphoma 2, is a proto-oncogene that encodes a key anti-apoptotic protein central to the regulation of programmed cell death, primarily by inhibiting mitochondrial outer membrane permeabilization (MOMP) to prevent the release of cytochrome c and subsequent activation of caspases.^[1] Discovered in 1984–1985 through its association with the t(14;18) chromosomal translocation in approximately 85% of follicular lymphoma cases, Bcl-2 was the first identified regulator of apoptosis, marking a paradigm shift in understanding how inhibition of cell death contributes to oncogenesis.^[2] As the founding member of the Bcl-2 protein family, it features a globular α-helical structure with four Bcl-2 homology (BH) domains (BH1–BH4), including a hydrophobic groove that binds pro-apoptotic family members such as BAX, BAK, and BH3-only proteins to maintain mitochondrial integrity and promote cell survival under stress.^[1]^[2] The Bcl-2 protein, approximately 26 kDa in its primary isoform (Bcl-2α), localizes to the outer mitochondrial membrane via a C-terminal transmembrane domain and also associates with the endoplasmic reticulum, where it modulates calcium signaling to further suppress apoptosis.^[2] Its anti-apoptotic function is tightly regulated by post-translational modifications like phosphorylation and ubiquitination, which influence its stability and interactions within the Bcl-2 family, comprising both pro- and anti-apoptotic members that collectively govern the intrinsic apoptosis pathway.^[2] Overexpression of Bcl-2, often due to genetic translocations or amplifications, disrupts the balance favoring survival and is implicated in the pathogenesis of hematologic malignancies such as chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and acute myeloid leukemia (AML), as well as solid tumors.^[1]^[2] Clinically, Bcl-2 has emerged as a prime therapeutic target, with BH3-mimetic drugs like venetoclax—a selective inhibitor that displaces pro-apoptotic proteins from Bcl-2's groove—receiving FDA approval in 2016 for relapsed/refractory CLL and later for AML in combination therapies, demonstrating significant response rates in clinical trials.^[2] Resistance to these inhibitors can arise from mutations in interacting proteins (e.g., acquired BAX mutations observed in up to 17% of relapsed AML cases following venetoclax therapy) or upregulation of related anti-apoptotic proteins like BCL-XL and MCL-1, prompting ongoing research into combination strategies, proteolysis-targeting chimeras (PROTACs), and antibody-drug conjugates.^[2] Beyond cancer, Bcl-2's role in neurodegeneration and autoimmunity highlights its broader physiological importance, with emerging applications in these areas under investigation.^[2]

Discovery and Gene

Discovery

The Bcl-2 gene was first identified in 1984 by Yoshihide Tsujimoto and colleagues, who cloned the chromosomal breakpoint at 18q21 in neoplastic B cells from patients with follicular lymphoma carrying the t(14;18) translocation.^[3] This translocation juxtaposes the Bcl-2 locus on chromosome 18 with the immunoglobulin heavy chain locus on chromosome 14, leading to deregulation and overexpression of Bcl-2.^[3] In a follow-up study the next year, Tsujimoto's team demonstrated that the Bcl-2 gene is directly interrupted by the t(14;18) breakpoint in most cases of follicular lymphoma, marking it as a proto-oncogene involved in B-cell malignancies.^[4] Building on these findings, early research in the late 1980s linked Bcl-2 overexpression to prolonged cell survival. In 1988, David L. Vaux, Suzanne Cory, and Jerry M. Adams reported that introduction of the Bcl-2 gene into hematopoietic cell lines promoted survival and cooperated with c-Myc to immortalize pre-B cells by inhibiting programmed cell death, or apoptosis.^[5] Throughout the 1990s, studies further established that the t(14;18) translocation-driven Bcl-2 overexpression in B-cell lymphomas suppressed apoptosis, allowing accumulation of long-lived malignant cells resistant to death signals. The broader significance of Bcl-2's anti-apoptotic role gained context from foundational discoveries in programmed cell death. In 2002, the Nobel Prize in Physiology or Medicine was awarded to Sydney Brenner, H. Robert Horvitz, and John E. Sulston for their genetic studies on organ development and cell death in Caenorhabditis elegans, which elucidated core mechanisms of apoptosis later connected to Bcl-2 regulation in mammals.^[6]

Gene and Expression

The BCL2 gene is located on the long arm of human chromosome 18 at the q21.33 band, spanning approximately 197 kb in a telomere-to-centromere orientation and comprising three exons separated by two introns, with the second intron being particularly large at around 370 kb.^[7]^[8] The first exon is untranslated, while exons 2 and 3 encode the functional protein domains.^[9] Transcriptional regulation of BCL2 involves multiple factors that bind to its dual promoters: the proximal P1 promoter, which is GC-rich and TATA-less, and the distal P2 promoter located upstream in the first intron. NF-κB activates BCL2 transcription by binding to κB sites in the promoter, promoting cell survival in response to inflammatory signals.^[10] In contrast, p53 represses BCL2 expression through direct binding to p53-responsive elements, thereby facilitating apoptosis in stressed cells.^[11] STAT3 also upregulates BCL2 by binding to STAT consensus sequences, particularly in hematopoietic cells under cytokine stimulation.^[12] Epigenetic modifications, such as hypermethylation of CpG islands in the promoter region, can silence BCL2 transcription in various cancers, including breast and hematologic malignancies.^[13] In normal physiology, BCL2 expression is prominent in long-lived cell populations, including lymphocytes (such as mature B and T cells), neurons, and epithelial cells of the colon, where it supports survival and prevents untimely apoptosis.^[14]^[15] Dysregulation frequently arises from the t(14;18)(q32;q21) chromosomal translocation, which places the BCL2 coding exons under the control of the immunoglobulin heavy chain (IGH) locus enhancers on chromosome 14, resulting in constitutive overexpression primarily in B lymphocytes.^[16] Alternative splicing of BCL2 pre-mRNA, influenced by the two promoters and facultative intronic sequences, generates at least nine transcript variants in humans, some of which produce truncated or modified isoforms with altered anti-apoptotic activity.^[17]

Structure and Isoforms

Protein Structure

Bcl-2 is a 239-amino acid protein that belongs to the Bcl-2 family of apoptosis regulators, characterized by four conserved Bcl-2 homology (BH) domains designated BH1, BH2, BH3, and BH4.^[18] These domains are defined by specific sequence motifs: BH1 and BH2 span approximately 20-30 amino acids each and are involved in dimerization, while BH3 is a short amphipathic α-helix of about 16 residues critical for protein-protein interactions; BH4, unique to anti-apoptotic members like Bcl-2, Bcl-xL, and Mcl-1, consists of a 20-residue N-terminal region that stabilizes the protein's core structure.^[19] The presence of all four BH domains distinguishes Bcl-2 from pro-apoptotic family members, which typically lack BH4 or contain only BH3.^[8] The overall three-dimensional structure of Bcl-2 features a compact helical bundle comprising eight α-helices (h1-h8), with two central hydrophobic helices (h5 and h6) flanked by amphipathic helices on the surface, forming a hydrophobic groove that accommodates binding partners.^[20] This architecture, first elucidated by solution NMR spectroscopy of the soluble domain (residues 1-218), reveals a fold similar to the bacterial toxin colicins but adapted for eukaryotic membrane interactions (PDB entry 1G5M).^[21] In the ligand-bound state, the groove is occupied by BH3 motifs from partner proteins, as seen in crystal structures where inhibitors mimicking BH3 helices insert into the cleft formed by h2-h4 and h7-h8, displacing loop regions for tight binding (e.g., PDB entry 4AQ3).^[22] The flexible loop connecting h1 and h2 (residues 30-80) is unstructured in solution, contributing to conformational dynamics essential for regulation. Bcl-2 primarily associates with cellular membranes through its C-terminal transmembrane (TM) domain, a 21-residue hydrophobic α-helix (residues 219-239) that anchors the protein to the outer mitochondrial membrane (MOM), as well as the endoplasmic reticulum and nuclear envelope.^[23] This TM domain enables tail-anchored insertion in a post-translational manner, with the N-terminal globular domain oriented toward the cytosol.^[24] In non-membrane-bound states, Bcl-2 can exist in the cytosol, and it possesses localization signals that allow association with nuclear compartments under certain conditions, such as stress-induced translocation.^[25] Post-translational modifications modulate Bcl-2's stability and localization, including phosphorylation at multiple sites within the flexible loop region. For instance, serine 70 (Ser70) is phosphorylated by c-Jun N-terminal kinase (JNK) in response to cellular stress, altering the protein's conformation and interaction potential.^[26] Ubiquitination targets Bcl-2 for proteasomal degradation, primarily via lysine residues in the N-terminal region, with dephosphorylation promoting ubiquitin ligase recruitment and reducing protein levels to fine-tune anti-apoptotic activity.^[27]

Isoforms

The BCL2 gene produces multiple protein isoforms through alternative splicing, with two primary variants identified in humans: isoform 1 (also known as BCL-2α), the full-length anti-apoptotic form consisting of 239 amino acids, and isoform 2 (BCL-2β), a shorter variant of 218 amino acids that lacks the C-terminal transmembrane domain encoded by exon 3.^[18]^[28] Alternative splicing occurs primarily at exon 3, where exclusion of this exon in isoform 2 results in a cytosolic protein unable to anchor to the mitochondrial outer membrane, thereby impairing its localization and function compared to the membrane-bound isoform 1. Isoform 1 is the predominant form expressed in various tissues and is notably overexpressed in many cancers, contributing to tumor cell survival by inhibiting apoptosis.^[28]^[29] Functional studies reveal distinct properties between the isoforms; isoform 1 effectively binds pro-apoptotic partners like BAX and BAK to prevent mitochondrial outer membrane permeabilization, while isoform 2 exhibits reduced anti-apoptotic activity, with reports indicating 50-70% lower inhibition of apoptosis in cellular assays due to altered binding affinity and localization defects. Rare isoforms, such as those resulting from deletion of exon 2 (ΔExon2), have been identified and may possess pro-apoptotic potential by disrupting normal BCL-2 family interactions, though their expression is low and context-dependent.^[30]^[31] Detection of these isoforms typically involves Western blot analysis using antibodies specific to the unique regions, such as N-terminal epitopes for isoform 1 or C-terminal sequences absent in isoform 2, allowing differentiation in tissue samples or cell lines.^[32]

Biological Function

Apoptosis Regulation

Bcl-2 plays a central role in regulating apoptosis by inhibiting mitochondrial outer membrane permeabilization (MOMP), a pivotal event in the intrinsic apoptotic pathway. As an anti-apoptotic member of the Bcl-2 family, it directly sequesters pro-apoptotic effectors Bax and Bak, preventing their conformational activation, oligomerization, and insertion into the mitochondrial outer membrane. This sequestration blocks the formation of pores that would otherwise allow the release of cytochrome c into the cytosol, thereby inhibiting the assembly of the apoptosome and downstream caspase activation.^[33]^[34] In addition to interacting with Bax and Bak, Bcl-2 antagonizes BH3-only proteins, which serve as sentinels for cellular stress. By binding to the BH3 domains of activators such as Bim, Bid (particularly its cleaved form tBid), and Puma, Bcl-2 neutralizes their ability to directly engage and activate Bax/Bak or to displace these effectors from other anti-apoptotic proteins. This multi-layered inhibition ensures that apoptotic signals fail to propagate unless the pro-apoptotic forces overwhelm the protective capacity of Bcl-2.^[35]^[19] The apoptotic threshold is finely tuned by the stoichiometric balance between Bcl-2 and its pro-apoptotic counterparts, a concept encapsulated in the rheostat model. In this framework, varying ratios of anti-apoptotic proteins like Bcl-2 to pro-apoptotic ones such as Bax modulate cellular sensitivity to death stimuli, allowing cells to integrate multiple survival and stress signals before committing to apoptosis. Experimental evidence from overexpression and knockout studies supports this dynamic equilibrium as a key determinant of cell fate.^[36]^[37] Bcl-2 also exerts non-mitochondrial control over apoptosis through its localization to the endoplasmic reticulum (ER) and nuclear envelope. At these sites, Bcl-2 maintains Ca²⁺ homeostasis by modulating the steady-state levels and release of Ca²⁺ from intracellular stores, thereby attenuating ER stress responses that can trigger apoptotic pathways via calpain activation or, in rodents, caspase-12. During cellular stress, this regulation prevents excessive Ca²⁺ efflux, which would otherwise amplify mitochondrial dysfunction and cell death.^[38]^[39]^[40]^[41]

Other Roles

Beyond its canonical function in apoptosis, Bcl-2 plays key roles in maintaining cellular homeostasis through regulation of mitochondrial dynamics. Bcl-2 family proteins such as Bcl-xL interact with dynamin-related protein 1 (Drp1), a GTPase essential for mitochondrial fission, thereby influencing the balance between fusion and fission events that shape mitochondrial morphology and function. For instance, Bcl-xL enhances Drp1 GTPase activity, promoting fission and supporting processes like synapse formation in neurons, while modulation of these interactions helps sustain mitochondrial network integrity under physiological conditions. Additionally, Bcl-2 family members regulate calcium signaling at endoplasmic reticulum (ER)-mitochondria contact sites, where they facilitate Ca²⁺ transfer that influences mitochondrial bioenergetics and dynamics, ensuring efficient energy production and cellular signaling without triggering cell death pathways.^[42] Bcl-2 also contributes to glucose homeostasis by modulating insulin secretion in pancreatic β-cells. In these cells, Bcl-2 suppresses glucose-induced metabolic signaling, including NAD(P)H production and cytosolic Ca²⁺ oscillations, which in turn limits insulin release under basal or substimulatory glucose levels. This regulatory effect integrates survival mechanisms with secretory control, preventing excessive insulin output that could disrupt systemic glucose balance, as evidenced by enhanced secretion observed in Bcl-2-deficient β-cells.^[43] In the context of cellular stress responses, Bcl-2 inhibits autophagy by directly binding to Beclin-1, a key component of the phosphatidylinositol 3-kinase (PI3K) complex required for autophagosome formation. Under nutrient deprivation, this interaction prevents Beclin-1 from activating Vps34, thereby suppressing starvation-induced autophagy and conserving cellular resources for survival; disruption of the Bcl-2-Beclin-1 complex, such as through phosphorylation or mutation, relieves this inhibition and promotes autophagic flux.^[44] This antiautophagic function operates primarily at the ER, distinct from Bcl-2's mitochondrial localization in apoptosis. Furthermore, Bcl-2 influences cell cycle progression by impeding the G1/S transition, a checkpoint critical for DNA replication. Through its antioxidant properties, Bcl-2 reduces intracellular reactive oxygen species (ROS) levels, which stabilizes the cyclin-dependent kinase inhibitor p27Kip1 and inhibits Cdk2 activity, leading to G0/G1 arrest and slower proliferation rates. This mechanism couples Bcl-2's prosurvival role with controlled cell division, as phosphomimetic mutants of Bcl-2 mimic this retardation by upregulating p27 expression.^[45]

Protein Interactions

Key Partners

Bcl-2, a central anti-apoptotic protein, forms direct interactions with multiple pro-apoptotic members of the Bcl-2 family to suppress mitochondrial outer membrane permeabilization. Specifically, Bcl-2 binds to Bax and Bak, the primary effectors of apoptosis, thereby preventing their conformational activation, membrane insertion, and homo-oligomerization that would otherwise lead to cytochrome c release.^[46] This interaction was first demonstrated through co-immunoprecipitation assays showing heterodimer formation in vivo. Additionally, BH3-only proteins such as Bad and Bim engage Bcl-2 via their BH3 domains in a competitive manner, displacing Bax and Bak to promote apoptosis; for instance, Bim exhibits high-affinity binding to Bcl-2's hydrophobic groove, sensitizing cells to death signals.^[47] Among anti-apoptotic homologs, Bcl-2 heterodimerizes with Bcl-xL and Mcl-1 to modulate survival thresholds and fine-tune apoptotic responses under stress conditions. These interactions stabilize the anti-apoptotic network, with Bcl-xL sharing structural similarity to Bcl-2 and binding overlapping partners to reinforce inhibition of pore formation.^[1] Mcl-1, in particular, forms dynamic complexes with Bcl-2 that adjust to cellular contexts, such as during development or inflammation.^[47] Beyond the Bcl-2 family, Bcl-2 associates with non-family proteins to influence diverse processes. Beclin-1, a key autophagy initiator, binds Bcl-2 at the endoplasmic reticulum and mitochondria, where Bcl-2 suppresses autophagosome formation by occupying Beclin-1's BH3-like domain.^[48] Calcineurin, a calcium-dependent phosphatase, interacts with Bcl-2 via its BH4 domain, leading to sequestration on cytoplasmic membranes and inhibition of NF-AT signaling to block Fas ligand expression.^[49] Furthermore, p53, the tumor suppressor, directly binds Bcl-2 through its DNA-binding domain, potentially repressing Bcl-2's anti-apoptotic activity in response to DNA damage.^[50] High-throughput screening approaches, including yeast two-hybrid systems and co-immunoprecipitation, have collectively identified numerous protein interactors for Bcl-2, spanning apoptosis regulators, signaling kinases, and metabolic enzymes, underscoring its role as a multifunctional hub.^[47]

Mechanisms

Bcl-2 exerts its anti-apoptotic function primarily through a hydrophobic groove formed by its BH1, BH2, and BH3 domains, which serves as the binding site for the amphipathic α-helix of BH3-only proteins. The BH3 helix inserts into this cleft via hydrophobic interactions, with key residues from the BH3 motif engaging conserved pockets within the groove, such as the h1-h4 sites. For instance, the binding of Bim BH3 to Bcl-2 exhibits high affinity, with a dissociation constant (Kd) of approximately 1 nM, underscoring the tight sequestration that prevents pro-apoptotic effectors like Bax from activating.^[51]^[52]^[53] Upon BH3 binding, Bcl-2 undergoes allosteric conformational changes that propagate from the groove to distant regions, including the C-terminal transmembrane (TM) helix. These alterations involve subtle shifts in the α-helical bundle, enhancing membrane insertion capability by exposing the TM helix for anchoring to the mitochondrial outer membrane. Such regulation fine-tunes Bcl-2's localization and activity, allowing dynamic responses to cellular stress signals.^[54]^[19]^[33] Post-translational modifications further modulate Bcl-2's interaction dynamics. JNK-mediated phosphorylation at sites like Ser70 reduces Bcl-2's affinity for Bax, promoting a shift toward pro-apoptotic signaling by impairing heterodimer stability. Similarly, ubiquitination targets Bcl-2 for proteasomal degradation, with E3 ligases facilitating polyubiquitin chain formation on lysine residues, thereby controlling Bcl-2 protein levels and preventing excessive anti-apoptotic activity. Although specific E3 ligases like XIAP have been implicated, the process ensures turnover in response to apoptotic cues.^[55]^[56]^[57] Dimerization of Bcl-2 with pro-apoptotic partners occurs through distinct models in membrane environments. The symmetric heterodimer model posits reciprocal BH3-groove interactions between Bcl-2 and Bax, forming stable pairs that inhibit Bax oligomerization. In contrast, the asymmetric model involves one-sided binding where Bcl-2's groove engages Bax's BH3 without reciprocity, influenced by membrane curvature and lipid composition, allowing context-dependent regulation of pore formation. These models highlight Bcl-2's versatility in membrane-embedded states.^[58]^[59]^[19]

Role in Disease

Cancer

Bcl-2 plays a pivotal oncogenic role in cancer by inhibiting apoptosis, thereby promoting the survival and proliferation of malignant cells. In follicular lymphoma, a common indolent B-cell malignancy, Bcl-2 is overexpressed in approximately 85-90% of cases due to the chromosomal translocation t(14;18)(q32;q21), which juxtaposes the BCL2 gene with the immunoglobulin heavy chain locus, leading to its constitutive expression.^[60]^[61] This overexpression sustains the survival of malignant B-cells by blocking programmed cell death, contributing to lymphomagenesis and disease persistence.^[60] Bcl-2 is also frequently expressed in various solid tumors, where it supports tumorigenesis and therapeutic resistance. In small cell lung cancer, Bcl-2 expression is observed in 70-80% of cases, often correlating with aggressive disease behavior.^[62]^[63] Similarly, in colorectal carcinoma, Bcl-2 positivity is reported in up to 70% of tumors, where it has been linked to chemoresistance by preventing drug-induced cell death.^[64]^[65] This resistance arises from Bcl-2's ability to sequester pro-apoptotic proteins, thereby evading therapy-induced apoptosis across multiple solid tumor types.^[66]^[65] In aggressive lymphomas, Bcl-2 exhibits synergistic effects with other oncogenes, amplifying its oncogenic potential. Double-hit lymphomas, characterized by concurrent rearrangements in MYC and BCL2 genes, demonstrate heightened resistance to standard therapies due to the combined promotion of proliferation (via MYC) and survival (via Bcl-2).^[67]^[68] This synergy drives rapid tumor progression and poor response to chemotherapy.^[67] As a prognostic marker, Bcl-2 expression holds clinical significance, particularly in breast cancer, where high levels in hormone receptor-negative or triple-negative subtypes are associated with unfavorable outcomes, with hazard ratios for recurrence ranging from 1.5 to 3.3.^[69]^[70] Targeted inhibition of Bcl-2 has emerged as a strategy to restore apoptosis sensitivity in these cancers.^[71]

Autoimmune Diseases

Bcl-2 plays a critical role in autoimmune diseases by inhibiting apoptosis in autoreactive lymphocytes, thereby impairing immune tolerance and allowing the persistence of self-reactive cells. In systemic lupus erythematosus (SLE), T lymphocytes exhibit elevated Bcl-2 expression, which contributes to defective apoptosis and the survival of autoreactive clones that drive autoantibody production and systemic inflammation.^[72] This overexpression is observed in circulating T cells from SLE patients, where Bcl-2 levels are significantly higher compared to healthy controls, correlating with disease activity and reduced susceptibility to activation-induced cell death.^[73] Similar patterns of Bcl-2 upregulation have been noted in other immune cells, further exacerbating the loss of peripheral tolerance in SLE.^[74] Animal models provide strong evidence for Bcl-2's involvement in autoimmunity through dysregulated apoptosis. In Bcl-2 transgenic mice, enforced overexpression of Bcl-2 in B-lymphoid cells leads to prolonged lymphocyte survival, polyclonal B-cell expansion, and the development of systemic autoimmune disease characterized by immune complex-mediated glomerulonephritis, resembling aspects of human SLE. These mice exhibit elevated serum autoantibodies, including anti-nuclear antibodies, and renal pathology driven by persistent autoreactive B cells that evade apoptosis. In type 1 diabetes, an imbalance favoring anti-apoptotic Bcl-2 over pro-apoptotic Bim in immune cells disrupts the deletion of autoreactive T cells; Bim deficiency, which shifts the balance toward Bcl-2 dominance, paradoxically protects non-obese diabetic (NOD) mice from disease onset by altering thymic selection toward regulatory T cells, highlighting how Bcl-2/Bim dysregulation can influence autoimmune progression.^[75] Conversely, in disease contexts, insufficient Bim activity relative to Bcl-2 promotes the accumulation of pathogenic T cells targeting pancreatic beta cells.^[76] Bcl-2 also contributes to autoimmunity by extending the lifespan of dendritic cells (DCs), which are key antigen-presenting cells that sustain chronic inflammation. Upregulation of Bcl-2 in DCs inhibits their apoptosis, leading to prolonged survival and enhanced priming of autoreactive T cells, thereby amplifying inflammatory responses in autoimmune settings.^[77] Transgenic expression of Bcl-2 in DCs has been shown to increase their longevity in vivo, resulting in heightened T-cell activation and autoantibody production, which can precipitate organ-specific autoimmunity.^[78] This mechanism underscores Bcl-2's role in maintaining dysregulated DC function, contributing to persistent antigen presentation and chronic tissue damage in diseases like rheumatoid arthritis and SLE. Therapeutically, targeting Bcl-2 holds promise for restoring apoptosis in autoimmune conditions, particularly by sensitizing resistant cells to death signals. In rheumatoid arthritis, synovial fibroblasts overexpress Bcl-2, conferring resistance to Fas-mediated apoptosis and perpetuating joint inflammation; reducing Bcl-2 levels, as demonstrated in models where Bcl-2 overexpression blocks Fas-induced cell death, sensitizes these cells to Fas ligand, promoting their elimination and potentially alleviating synovitis.^[79] This approach aligns with broader strategies to modulate Bcl-2 family dynamics, offering a means to enhance immune tolerance without broad immunosuppression.^[80]

Neurological Disorders

Bcl-2 plays a protective role in neurodegenerative diseases by inhibiting apoptosis in neurons exposed to pathological stressors. In models of Alzheimer's disease (AD), overexpression of Bcl-2 has been shown to prevent neuronal death induced by amyloid-beta (Aβ) peptides, a hallmark of AD pathology. This neuroprotection occurs through mechanisms that enhance resistance to Aβ toxicity, including stabilization of mitochondrial membranes and reduction in caspase activation. For instance, in transgenic mouse models of AD, Bcl-2 overexpression prevents caspase-mediated cleavage of the amyloid precursor protein (APP), thereby attenuating downstream apoptotic signaling.^[81] In schizophrenia, postmortem analyses of brain tissue reveal reduced Bcl-2 expression in the prefrontal and temporal cortex, suggesting impaired anti-apoptotic regulation that may contribute to neuronal vulnerability. This downregulation is associated with an elevated Bax/Bcl-2 ratio, promoting a pro-apoptotic state in affected regions.^[82]^[83] Bcl-2 is upregulated in response to hypoxia following ischemic stroke, promoting neuronal survival by suppressing mitochondrial outer membrane permeabilization and cytochrome c release. This adaptive response helps limit infarct expansion in the penumbra region. In rodent models of focal cerebral ischemia, Bcl-2 knockout exacerbates brain damage, resulting in larger infarct volumes and worsened neurological outcomes compared to wild-type controls, underscoring its essential role in post-ischemic neuroprotection.^[84]^[85] Emerging evidence suggests Bcl-2 modulates alpha-synuclein aggregation in Parkinson's disease (PD) models through mitochondrial protection. Overexpression of Bcl-2 or its homologs, such as Buffy in Drosophila, rescues dopaminergic neuron loss induced by alpha-synuclein overexpression by preserving mitochondrial integrity and preventing fission-fusion imbalances. This protective effect mitigates alpha-synuclein-mediated toxicity, highlighting Bcl-2's potential in countering PD-related mitochondrial dysfunction.^[86]

Clinical Applications

Diagnostic Use

Bcl-2 is widely utilized as a biomarker in clinical pathology for assessing apoptosis dysregulation in various malignancies, particularly through detection methods that inform diagnosis and prognosis. In hematological cancers such as lymphomas, immunohistochemistry (IHC) employing monoclonal antibodies like clone 124 enables the identification of Bcl-2 overexpression in tissue biopsies. This antibody specifically targets the Bcl-2 protein, producing cytoplasmic staining in positive cells without cross-reactivity to related proteins like Bcl-x or Bax.^[87] Scoring systems for IHC typically combine staining intensity (graded 0-3+, where 0 indicates no staining and 3+ strong staining) with the proportion of positive tumor cells, allowing pathologists to quantify expression levels in formalin-fixed paraffin-embedded samples from lymphoma patients.^[88] These assessments are crucial for subclassifying aggressive lymphomas and guiding therapeutic decisions. The prognostic utility of Bcl-2 expression is well-established in diffuse large B-cell lymphoma (DLBCL), where positivity correlates with increased risk of relapse and reduced survival. Studies have shown that Bcl-2-positive DLBCL cases exhibit poorer outcomes compared to negative cases, with 3-year overall survival rates of 37% versus 63%, respectively, highlighting its role as an independent adverse prognostic factor in patients treated with standard regimens like R-CHOP.^[89] This association underscores Bcl-2's value in risk stratification, as overexpression often indicates resistance to chemotherapy-induced apoptosis and is integrated into multimodal prognostic models alongside other markers like MYC.^[90] In chronic lymphocytic leukemia (CLL), Bcl-2 detection via flow cytometry and quantitative PCR (qPCR) supports minimal residual disease (MRD) monitoring post-treatment, leveraging its consistent overexpression in leukemic B-cells. Flow cytometry panels incorporating anti-Bcl-2 antibodies can quantify protein levels on CLL cells as part of MRD assessment, where standard sensitivity reaches 10^{-4}, while qPCR targets Bcl-2 mRNA transcripts for molecular assessment of disease burden.^[91] These techniques enable early detection of relapse risk, with undetectable MRD (<10^{-4}) linked to superior progression-free survival in venetoclax-treated patients.^[92] Bcl-2-based MRD evaluation complements standard immunophenotypic markers like CD5 and CD23, providing a comprehensive view of residual disease dynamics.

Targeted Therapies

Targeted therapies for Bcl-2 focus on inhibiting its anti-apoptotic function to restore the intrinsic apoptosis pathway in cancer cells, particularly in hematologic malignancies where Bcl-2 overexpression promotes survival.^[93] The primary strategies include BH3 mimetics, which are small-molecule inhibitors that mimic the BH3 domain of pro-apoptotic proteins such as Bim or Bid, binding to the hydrophobic groove of Bcl-2 and displacing these effectors to activate Bax and Bak for mitochondrial outer membrane permeabilization.^[94] Another approach uses antisense oligonucleotides, such as oblimersen, which hybridize to Bcl-2 mRNA, triggering its RNase H-mediated degradation and thereby reducing Bcl-2 protein levels to sensitize cells to apoptosis.^[95] Clinical development of these therapies faces key challenges, including on-target toxicities and acquired resistance. Although selective Bcl-2 inhibitors like venetoclax minimize issues seen with broader anti-apoptotic targeting, thrombocytopenia remains a concern in some regimens due to the role of related family members like Bcl-xL in platelet survival, necessitating dose adjustments or selectivity improvements.^[96] Resistance often emerges through upregulation of alternative anti-apoptotic proteins, such as Mcl-1, which sequesters pro-apoptotic factors not affected by Bcl-2 inhibition, leading to incomplete tumor cell killing.^[97] To overcome these hurdles, Bcl-2 inhibitors are frequently combined with other agents for synergistic effects. In chronic lymphocytic leukemia (CLL), pairings with chemotherapy or anti-CD20 antibodies like rituximab enhance apoptosis by concurrently targeting B-cell signaling and survival pathways.^[98] Similarly, combinations with BTK inhibitors, such as ibrutinib, disrupt complementary pro-survival mechanisms in CLL, yielding higher response rates and deeper remissions than monotherapy.^[99] Bcl-2 inhibitors have gained regulatory approvals primarily for hematologic malignancies, including CLL and acute myeloid leukemia, driving market growth. The global BCL-2 inhibitors market reached approximately $2.55 billion as of 2025.^[100] Recent developments include the conditional approval of lisaftoclax, a novel Bcl-2 inhibitor, in China for relapsed/refractory CLL/SLL in July 2025.^[101]

Targeted Therapies

Oblimersen

Oblimersen, also known as G3139 or Genasense, is an 18-mer phosphorothioate antisense oligonucleotide designed to target the Bcl-2 mRNA by binding to its first six codons in the open reading frame.^[102] This first-generation nucleic acid-based therapy aims to inhibit Bcl-2 expression, a key anti-apoptotic protein overexpressed in various cancers, thereby sensitizing tumor cells to chemotherapy-induced apoptosis. Developed by Genta Incorporated, oblimersen represents an early attempt at antisense technology for oncology, focusing on post-transcriptional gene silencing rather than small-molecule inhibition. The mechanism of action involves the formation of a DNA-RNA hybrid upon binding of oblimersen to the complementary Bcl-2 mRNA sequence, which recruits RNase H enzymes to cleave the mRNA strand, leading to its degradation and subsequent reduction in Bcl-2 protein levels. In vitro studies have demonstrated that this process downregulates Bcl-2 expression by 60-90% in cancer cell lines, enhancing susceptibility to apoptotic stimuli without directly affecting cell proliferation. Unlike steric-blocking oligonucleotides, oblimersen's phosphorothioate backbone facilitates this RNase H-mediated pathway, though it also contributes to off-target effects such as immune stimulation via Toll-like receptor activation. This approach provided proof-of-principle for antisense-mediated Bcl-2 inhibition in human tumors, with documented reductions in Bcl-2 protein observed in patient-derived samples.^[103] A pivotal randomized phase III trial conducted in 2004 evaluated oblimersen in combination with dacarbazine for chemotherapy-naive patients with advanced malignant melanoma, involving over 700 participants across multiple centers. The study aimed to assess overall survival (OS) as the primary endpoint, but results showed no statistically significant OS benefit for the combination arm compared to dacarbazine alone, with median survival of approximately 9.0 months versus 7.8 months. While subgroup analyses suggested improvements in progression-free survival and response rates in patients with low-normal lactate dehydrogenase levels, the overall lack of OS advantage led to questions about its clinical utility in this setting. Subsequent retrospective reviews confirmed that baseline biomarkers like serum lactate dehydrogenase were predictive of outcomes but did not alter the trial's negative conclusion for broad approval.^[104]^[105] Despite promising phase I/II data in hematologic malignancies, oblimersen has not received FDA approval, with the agency issuing a non-approvable letter in 2006 for both melanoma and chronic lymphocytic leukemia indications due to insufficient evidence of clinical benefit. Development was further limited after negative results from the AGENDA phase III trial in melanoma (reported in 2009-2011), which confirmed no progression-free survival or OS advantage, leading to discontinuation of the program post-2010. In acute myeloid leukemia (AML), oblimersen was explored in phase I/II trials combined with chemotherapy, showing preliminary activity such as improved complete remission rates in some cohorts, but no phase III advancement occurred, restricting its use to investigational settings.^[106]^[107]^[108] Common side effects associated with oblimersen include fever (pyrexia in up to 33% of patients), thrombocytopenia (frequently grade 3/4, especially when combined with chemotherapy), fatigue, nausea, and hypotension, often linked to its infusion and immune-modulatory properties. In AML trials, additional hematologic toxicities such as neutropenia were observed, mirroring standard chemotherapy effects, with no unique cardiac risks identified. These adverse events contributed to dose-limiting challenges, underscoring the hurdles in translating antisense therapies to clinical practice.^[109]^[110]

ABT-737 and Navitoclax

ABT-737, developed in 2005 by Abbott Laboratories, represents the first potent small-molecule BH3 mimetic inhibitor targeting the anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-xL, and Bcl-w, with dissociation constants (Ki) below 1 nM for each.^[111] This compound binds to the BH3-binding groove of these proteins, displacing pro-apoptotic BH3-only proteins such as Bim and Bad, thereby promoting mitochondrial outer membrane permeabilization and apoptosis.^[111] In preclinical models, ABT-737 demonstrated significant efficacy as a single agent, inducing complete regression of established tumors in xenograft models of lymphoma and small-cell lung carcinoma, with improved survival and cures observed in a substantial proportion of treated mice.^[111] Navitoclax (ABT-263), an orally bioavailable analog of ABT-737, was designed to retain the high-affinity binding profile (Ki ≤ 1 nM) to Bcl-2, Bcl-xL, and Bcl-w while improving pharmacokinetic properties for clinical use. Between 2009 and 2015, phase I and II trials evaluated navitoclax in relapsed or refractory chronic lymphocytic leukemia (CLL), reporting an overall response rate (ORR) of approximately 35-42% in monotherapy settings, with notable reductions in lymph node size and clearance of malignant cells from the blood. However, clinical development was constrained by dose-limiting thrombocytopenia, attributed to Bcl-xL inhibition affecting platelet survival, alongside neutropenia in some cohorts. The pan-anti-apoptotic binding of navitoclax enables it to overcome resistance mechanisms in B-cell malignancies driven by Bcl-2 overexpression, such as the t(14;18) translocation in follicular lymphoma, where phase I data showed an ORR of 75% (9/12 patients), including complete responses in over 40%. This activity highlights its potential to sensitize resistant tumors to apoptosis by broadly neutralizing multiple survival signals within the Bcl-2 family. As of 2025, navitoclax monotherapy development has been discontinued due to on-target toxicities like thrombocytopenia, shifting focus to combination regimens that mitigate these effects while enhancing efficacy.^[112] It is currently under investigation in combinations for solid tumors, such as with docetaxel in advanced malignancies (e.g., NCT02079740, active but not recruiting as of November 2025).^[113]

Venetoclax

Venetoclax, also known as ABT-199, is a small-molecule BH3 mimetic that was developed in 2011 as a highly selective inhibitor of the anti-apoptotic protein Bcl-2, addressing limitations of earlier non-selective compounds like navitoclax by minimizing thrombocytopenia. It exhibits exceptional potency and selectivity, with a dissociation constant (Ki) of 0.02 nM for Bcl-2 compared to 59 nM for Bcl-xL, enabling targeted disruption of Bcl-2-dependent survival pathways in malignant cells while sparing platelets. The U.S. Food and Drug Administration (FDA) granted accelerated approval for venetoclax in 2016 for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) harboring a 17p deletion, marking it as the first selective Bcl-2 inhibitor approved for clinical use. Venetoclax exerts its therapeutic effect by binding to the BH3-binding groove on the surface of Bcl-2, thereby displacing pro-apoptotic BH3-only proteins such as Bim and activating the intrinsic apoptotic pathway in cancer cells.^[114] This mechanism leads to rapid tumor debulking, with approximately 70% of CLL patients experiencing significant lymph node reduction within weeks of initiation, often necessitating tumor lysis syndrome prophylaxis due to the swift onset of cell death.^[115] The phase 3 MURANO trial, reported in 2018, demonstrated the efficacy of fixed-duration venetoclax combined with rituximab in relapsed or refractory CLL, achieving a median progression-free survival (PFS) of 54 months compared to 17 months with bendamustine-rituximab, establishing it as a transformative regimen for this population. By 2024, venetoclax approvals had expanded to include frontline combinations for acute myeloid leukemia (AML), such as with hypomethylating agents like azacitidine, showing improved complete remission rates and overall survival in older, unfit patients; ongoing trials further integrate it with intensive chemotherapy like "7+3" regimens for fit AML patients. Recent 2025 data from long-term follow-up of fixed-duration regimens, including MURANO's final analysis confirming sustained PFS benefits up to 54.7 months, underscore venetoclax's role in enabling time-limited therapy and deep minimal residual disease responses in CLL.^[116] However, resistance can emerge through acquired BCL2 mutations, notably G101V in the BH3-binding domain, which reduces drug affinity and is observed in relapsed patients on continuous monotherapy.^[117]

Sonrotoclax

Sonrotoclax (BGB-11417) is an oral, second-generation Bcl-2 inhibitor developed by BeiGene to overcome resistance mechanisms associated with first-generation inhibitors like venetoclax, particularly in hematologic malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).^[118] It exhibits improved pharmacokinetics, including a short plasma half-life of approximately 4 hours, which supports once-daily dosing and contributes to a favorable safety profile with reduced risk of prolonged exposure-related toxicities.^[119] Sonrotoclax demonstrates high selectivity for Bcl-2 over other anti-apoptotic proteins, minimizing off-target effects such as platelet toxicity observed with earlier non-selective inhibitors.^[120] The binding profile of sonrotoclax shows potent affinity for both wild-type and mutant forms of Bcl-2, with IC₅₀ values of 0.035 nM for wild-type and 0.28 nM for the G101V mutant, a common venetoclax resistance mutation that impairs drug binding.^[121] This enhanced potency against mutant Bcl-2 enables sonrotoclax to restore apoptotic signaling in resistant cells, addressing mechanisms like the G101V alteration that reduce venetoclax efficacy.^[120] Preclinical studies confirm its superior cytotoxic activity in hematologic cancer models harboring these mutations compared to venetoclax.^[121] Phase I/II trials (BGB-11417-101, NCT04277637), initiated in 2020 and reporting data through 2025, have evaluated sonrotoclax as monotherapy and in combinations for relapsed/refractory CLL and AML.^[122] In venetoclax-relapsed or refractory CLL, sonrotoclax monotherapy yielded an overall response rate (ORR) of 94% at the 320 mg dose, with 44% complete responses and 75% undetectable minimal residual disease.^[123] Combination therapy with zanubrutinib, a BTK inhibitor, achieved an ORR of 97% in relapsed/refractory CLL/SLL patients, including those previously treated with venetoclax, with 57% complete responses and no tumor lysis syndrome events.^[124] These results highlight sonrotoclax's efficacy in venetoclax-resistant settings, supported by its reduced platelet impact and overall tolerability. As of 2025, sonrotoclax has advanced to phase III development, with the CELESTIAL-TNCLL trial (NCT06073821), an ongoing study assessing sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in treatment-naive CLL.^[125] Early data from frontline CLL combinations indicate high minimal residual disease clearance rates (up to 100% at 320 mg) and promising progression-free survival, underscoring the potential of these regimens.

Lisaftoclax

Lisaftoclax (APG-2575) is a novel, orally bioavailable, selective small-molecule inhibitor of B-cell lymphoma 2 (Bcl-2) developed by Ascentage Pharma for the treatment of hematologic malignancies. It functions as a BH3 mimetic, binding with high affinity (Ki < 0.1 nmol/L) to the BH3-binding groove of wild-type Bcl-2 to restore apoptosis in cancer cells overexpressing the protein. Unlike venetoclax, lisaftoclax exhibits a pharmacokinetic profile supporting a shorter, daily dose ramp-up over 5-7 days rather than 5 weeks, enabling once-daily oral administration and potentially reducing treatment delays. Preclinical studies indicate it maintains potency against certain Bcl-2 mutants associated with venetoclax resistance when combined with other agents, though monotherapy binding to mutants requires further validation.^[126]^[127]^[128]^[129] In July 2025, China's National Medical Products Administration (NMPA) approved lisaftoclax as the first Bcl-2 inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy, based on phase II data demonstrating an overall response rate (ORR) of up to 72% and complete response (CR) rate of 45% in relapsed/refractory CLL/SLL. The approval was supported by a multicenter phase II study (NCT04684563) showing rapid tumor reduction and manageable tumor lysis syndrome risk with the abbreviated ramp-up. Safety profiles were favorable, with grade 3/4 neutropenia occurring in 34% of patients, lower than the 50-60% typically reported with venetoclax in similar settings, and only 3% requiring dose reductions due to hematologic toxicity.^[130]^[131]^[132]^[128] At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, phase Ib/II data (NCT04964518) on lisaftoclax plus azacitidine in 103 patients with treatment-naïve or venetoclax-exposed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) were presented in an oral report, highlighting activity in venetoclax-refractory subsets. In relapsed/refractory AML/MPAL patients previously exposed to venetoclax (n=18), the ORR was 39% with a 28-day cycle and 50% with a 14-day cycle, including CR rates of 28% and 37.5%, respectively; in high-risk MDS (n=2), ORR reached 50% with 50% CR. These responses occurred despite prior venetoclax failure, suggesting potential to overcome resistance mechanisms, with median response duration exceeding 12 months in responders. Grade 3/4 neutropenia was reported in 40% of all patients, comparable to or lower than venetoclax combinations (50-70%), with no dose-limiting toxicities and a maximum tolerated dose not reached.^[133]^[134]^[135] Ongoing global phase III trials are evaluating lisaftoclax's role in frontline and refractory settings. The GLORA-4 study (NCT06641414), cleared by the U.S. FDA and European Medicines Agency in August 2025, is a randomized, double-blind trial comparing lisaftoclax plus azacitidine versus placebo plus azacitidine in treatment-naïve higher-risk MDS, assessing overall survival and CR as primary endpoints. Additional phase III efforts include the GLORA trial in previously treated CLL/SLL and combinations with hypomethylating agents (HMAs) like azacitidine in MDS/AML, aiming to confirm superiority over venetoclax-based regimens in efficacy and myelosuppression. No direct head-to-head phase III versus venetoclax has been identified as of November 2025, though comparative safety data favor lisaftoclax's dosing convenience.^[136]^[137]^[138]

Emerging Inhibitors

ICP-248 (mesutoclax), developed by InnoCare Pharma, is an orally bioavailable, selective BCL-2 inhibitor designed to restore apoptosis in cancer cells with reduced hematologic toxicity compared to earlier agents. In a phase I dose-escalation and expansion study (NCT05728658) for relapsed/refractory (R/R) B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), ICP-248 demonstrated a favorable safety profile with no dose-limiting toxicities observed across doses of 50-200 mg daily and most treatment-emergent adverse events (TEAEs) being grade 1-2, primarily hematologic such as neutropenia and thrombocytopenia. As of December 2024, among 20 evaluable CLL/SLL patients receiving ≥100 mg, the overall response rate (ORR) was 80%, with a complete response rate (CRR) of 15%, including 81.8% ORR in the BTK inhibitor-failure subgroup (n=11).^[139] In February 2025, China's NMPA approved a phase III registrational trial of ICP-248 in combination with orelabrutinib for R/R CLL/SLL.^[140] BGB-21447, a next-generation oral BCL-2 inhibitor from BeOne Medicines (formerly BeiGene), targets overexpressed BCL-2 in B-cell malignancies to induce apoptosis with potentially improved tolerability. In the ongoing phase I dose-escalation study (NCT05828589) for R/R mature B-cell non-Hodgkin lymphomas, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL), BGB-21447 was administered at doses of 10-320 mg using a ramp-up schedule. As of May 2025, among 44 enrolled patients (median 3 prior lines), treatment-related TEAEs occurred in 79.5%, with grade ≥3 events in 40.9% mainly consisting of leukopenia (56.8%) and neutropenia (50.0%), and no clinical tumor lysis syndrome reported. Preliminary efficacy showed an ORR of 38.1% (CRR 14.3%) in FL/MZL (n=21) and 33.3% (CRR 16.7%) in DLBCL (n=12).^[141] Beyond small-molecule inhibitors, research trends in BCL-2 targeting emphasize proteolysis-targeting chimeras (PROTACs) for ubiquitin-mediated degradation of BCL-2 family proteins, offering potential advantages in overcoming resistance from protein stabilization. Preclinical studies in 2024 demonstrated that PROTACs inducing dual degradation of BCL-2 and BCL-xL effectively sensitized small-cell lung cancer cells to apoptosis, with selective targeting sparing normal platelets. Similarly, dual BCL-2/MCL-1 inhibitors in preclinical models, such as those evaluated in high-risk neuroblastoma, exhibited synergistic antitumor effects by simultaneously blocking complementary anti-apoptotic pathways, though clinical translation remains challenged by toxicity profiles.^[142]^[143] Combination strategies integrating BCL-2 inhibitors with Bruton tyrosine kinase inhibitors (BTKis) are advancing in early trials to enhance efficacy in resistant CLL. For instance, lisaftoclax (APG-2575) combined with acalabrutinib in R/R CLL patients previously exposed to venetoclax (n=14) yielded an ORR of 86% and 12-month progression-free survival (PFS) of 84% at ASH 2024, with median PFS not reached and primarily grade 1-2 TEAEs like neutropenia. These approaches highlight a shift toward fixed-duration, tolerable regimens to improve outcomes in BTKi-pretreated populations.

References

[1]
The BCL-2 protein family: from discovery to drug development - Nature
Apr 9, 2025 · The landmark discovery of the BCL-2 gene and then its function marked the identification of inhibition of apoptotic cell death as a crucial novel mechanism ...
[2]
The BCL2 family: from apoptosis mechanisms to new advances in ...
The B cell lymphoma 2 (BCL2) protein family critically controls apoptosis by regulating the release of cytochrome c from mitochondria.
[3]
Cloning of the Chromosome Breakpoint of Neoplastic B Cells with ...
This probe detected rearrangement of the homologous DNA segment in the leukemic cells and in follicular lymphoma cells with the t(14:18) chromosome ...
[4]
Involvement of the bcl-2 Gene in Human Follicular Lymphoma
The gene coding for these transcripts (the bcl-2 gene) seems to be interrupted in most cases of follicular lymphomas carrying the t(14;18) chromosomal ...
[5]
Bcl-2 gene promotes haemopoietic cell survival and cooperates with ...
Sep 29, 1988 · Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. David L. Vaux,; Suzanne Cory &; Jerry M.
[6]
Involvement of the bcl-2 gene in human follicular lymphoma - PubMed
Jun 21, 1985 · The gene coding for these transcript (the bcl-2 gene) seems to be interrupted in most cases of follicular lymphomas carrying the t(14;18) ...
[7]
The Nobel Prize in Physiology or Medicine 2002 - Press release
Oct 7, 2002 · He described the visible steps in the cellular death process and demonstrated the first mutations of genes participating in programmed cell ...
[8]
https://atlasgeneticsoncology.org/gene/49/bcl2-%28b-cell-leukemia-lymphoma-2%29
[9]
BCL2 (B-Cell Leukemia/Lymphoma 2)
Dec 1, 2017 · BCL2 is normally located on chromosome 18q21.33 in a telomere to centromere orientation. The molecular consequence of the t(14;18) juxtaposes of ...Missing: size | Show results with:size
[10]
Alternative promoters and exons, somatic mutation and ... - PubMed
The normal human Bcl-2 gene has a three exon structure with an untranslated first exon, a facultative 220 bp intron I, but an enormous 370 kb intron II. S1 ...Missing: genomic | Show results with:genomic
[11]
Transcriptional regulation of bcl-2 by nuclear factor kappa B and its ...
The bcl-2 gene is transcriptionally regulated by NF-kappa B, linking the TNF-alpha pathway to Bcl-2 expression, which is linked to hormone-resistant prostate ...
[12]
Mechanisms of transcriptional regulation by p53 - Nature
Nov 10, 2017 · p53 is a transcription factor that suppresses tumor growth through regulation of dozens of target genes with diverse biological functions.The Disordered C-Terminus... · P53 Is The Ultimate Direct... · Regulatory Diversity In The...<|control11|><|separator|>
[13]
BCL-2 expression is mainly regulated by JAK/STAT3 pathway in ...
Jul 14, 2006 · Interestingly, STAT3 transcript levels were higher in the more primitive human hematopoietic CD34+CD38− cells than in their counterpart CD34+ ...
[14]
BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to ...
BCL-2 expression is silenced by the DNA methylation of exon 2 in human breast cancer and correlates with poor survival. A, the relationship between BCL-2 ...Tcga Breast Cancer Data... · Clonal Bisulfite Sequencing · Results
[15]
BCL‐2 expression in adult and embryonic non‐haematopoietic tissues
Bcl-2 protein expression is mainly observed in cell populations with a long life and/or proliferating ability such as duct cells in exocrine glands, basal ...
[16]
Bcl-2 - NordiQC - Immunohistochemical Quality Control
In lymphocytes, Bcl-2 is highly expressed in T-cells, pro-B cells and mature B-cells (where lifespan is extended) while downregulated in germinal centre B-cells ...
[17]
t(14;18) Translocations and Risk of Follicular Lymphoma - PMC - NIH
The chromosomal translocation t(14;18)(q32;q21) is characteristic of follicular lymphoma and a frequent abnormality in other types of non-Hodgkin lymphoma (NHL) ...Missing: 1984 | Show results with:1984
[18]
Gene: BCL2 (ENSG00000171791) - Summary - Ensembl
Chromosome 18: 63,123,346-63,320,128 reverse strand. This gene has 9 transcripts (splice variants), 225 orthologues, 8 paralogues and is associated with 78 ...
[19]
BCL2 - Apoptosis regulator Bcl-2 - Homo sapiens (Human) - UniProt
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells.Missing: span | Show results with:span
[20]
Mechanisms of Action of Bcl-2 Family Proteins - PMC
The Bcl-2 family of proteins controls a critical step in commitment to apoptosis by regulating permeabilization of the mitochondrial outer membrane (MOM).
[21]
Solution structure of the antiapoptotic protein bcl-2 - PNAS
A fragment coding amino acids 1–218 of Bcl-2(1) (Fig. 1) was obtained from Daudi mRNA (CLONTECH) by reverse transcription (RT)–PCR using an RT PCR kit (Roche ...Results And Discussion · Quality Of The Bcl-2... · Description Of Bcl-2...<|separator|>
[22]
1G5M: HUMAN BCL-2, ISOFORM 1 - RCSB PDB
Mar 21, 2001 · The structures of the two Bcl-2 isoforms consist of 6 alpha-helices with a hydrophobic groove on the surface similar to that observed for the homologous ...
[23]
4AQ3: HUMAN BCL-2 WITH PHENYLACYLSULFONAMIDE ...
Jun 6, 2012 · A series of phenylacylsulfonamides has been prepared as antagonists of Bcl-2/Bcl-xL. In addition to potent binding affinities for both Bcl-2 and Bcl-xL,
[24]
The C-terminal sequences of Bcl-2 family proteins mediate ...
Most Bcl-2 family members possess a C-terminal sequence (CTS) that localizes and binds the protein to intracellular membranes such as the MOM and endoplasmic ...
[25]
BCL-2 and BOK regulate apoptosis by interaction of their C-terminal ...
Jul 24, 2024 · The Bcl-2 family proteins BCL-2 and BOK interact via their transmembrane domains (TMDs) at the endoplasmic reticulum (ER).
[26]
Characterization of the signal that directs Bcl-x L , but not Bcl-2, to ...
The signal is present in numerous proteins known to be directed to the MOM. Bcl-2 lacks the signal and therefore localizes to several intracellular membranes.
[27]
Novel role for JNK as a stress-activated Bcl2 kinase - PubMed - NIH
Jun 29, 2001 · Interleukin (IL)-3-induced Bcl2 phosphorylation at Ser(70) may be required for its full and potent antiapoptotic activity.
[28]
Dephosphorylation Targets Bcl-2 for Ubiquitin-dependent Degradation
Taken together, ubiquitin-dependent proteolytic degradation decreases Bcl-2 protein levels and thereby renders cells susceptible for apoptotic stimuli. Moreover ...
[29]
BCL-2 family isoforms in apoptosis and cancer - PMC
Feb 21, 2019 · Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988 ...
[30]
BCL-2 family isoforms in apoptosis and cancer | Cell Death & Disease
Feb 21, 2019 · The structure of the BCL-2α protein is similar to BCL-XL, with two central hydrophobic helices (α1 and α2) surrounded by five α-helices, and a C ...
[31]
Identification and functional comparison of Bcl2 splicing isoforms in ...
Apr 2, 2020 · Taken together, our results demonstrate previously unknown functional differences in Bcl2 alternative splicing isoforms in ESCs, and lay the ...
[32]
Identification and functional comparison of Bcl2 splicing isoforms in ...
There are two alternative splicing variants of Bcl2 in mouse, Bcl2α and Bcl2β [12]. Bcl2α consists of four BH domains (BH1-4) and a transmembrane (TM) domain.
[33]
20 years of research on a non-typical protein from the BCL-2 family
Apr 8, 2023 · As a result of alternative splicing, BCL-G proteins of different lengths can be generated in humans, including short (BCL-GS), median (BCL-GM), ...<|control11|><|separator|>
[34]
Bcl‐2 changes conformation to inhibit Bax oligomerization
Apr 27, 2006 · Bcl-2 functions as an inhibitor of mitochondrial permeabilization by changing conformation in the mitochondrial membrane to bind membrane‐inserted Bax monomers.
[35]
Mechanisms of cytochrome c release from mitochondria - Nature
May 5, 2006 · On the other hand, overexpression of BCL-2 or BCL-XL is able to block MOMP induced by ectopically expressed BH3-only proteins and mediated by ...
[36]
BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing ...
BCL-2, BCL-X L indicates these antiapoptotics sequester BH3 domain-only molecules in stable mitochondrial complexes, preventing the activation of BAX, BAK.
[37]
Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell ...
Bcl-2 has proved to be unique among protooncogenes in blocking programmed cell death rather than promoting proliferation.
[38]
The rheostat in the membrane: BCL-2 family proteins and apoptosis
Oct 25, 2013 · Many signals for cellular life and death are regulated by the BCL-2 family proteins and converge at mitochondria, where cell fate is ultimately decided.
[39]
Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum - Nature
May 26, 2006 · Recent data have revealed an unexpected role of Bcl-2 in modulating the steady-state levels and agonist-dependent fluxes of Ca2+ ions.
[40]
Maintenance of Calcium Homeostasis in the Endoplasmic Reticulum ...
In summary, the findings suggest that Bcl-2 maintains Ca2+ homeostasis within the ER, thereby inhibiting apoptosis induction by TG. The oncogene bcl-2 encodes a ...Missing: envelope | Show results with:envelope
[41]
Bcl-2 decreases the free Ca2+ concentration within the endoplasmic ...
These results suggest that Bcl-2 decreases the free Ca 2+ concentration within the ER lumen by increasing the Ca 2+ permeability of the ER membrane.
[42]
Connecting mitochondrial dynamics and life-or-death events via Bcl ...
Bcl-2 family proteins also have multifaceted influences on cells and mitochondria, including calcium handling, autophagy and energetics, as well as the ...
[43]
https://doi.org/10.2337/db11-1464
[44]
https://doi.org/10.1016/j.cell.2005.07.002
[45]
BCL-2 family proteins: changing partners in the dance towards death
Nov 17, 2017 · The BCL-2 family of proteins controls cell death primarily by direct binding interactions that regulate mitochondrial outer membrane permeabilization (MOMP).Missing: key | Show results with:key
[46]
Suppression of signalling through transcription factor NF-AT ... - Nature
Apr 17, 1997 · Here we report that Bcl-2 forms a tight complex with calcineurin, resulting in the targeting of calcineurin to Bcl-2 sites on cytoplasmic membranes.
[47]
Structures of p53/BCL-2 complex suggest a mechanism for ... - Nature
Jul 18, 2023 · p53 regulates the activity of the BCL-2 family through transcription-dependent and transcription-independent pathways. As a nuclear ...
[48]
Structural Details of BH3 Motifs and BH3-Mediated Interactions
May 24, 2022 · (A) represents the canonical topology, with one molecule of the BCL2 protein bound to a single BH3 peptide (PDB ID: 2M04). Panel (B) and (D) ...
[49]
Structural Details of BH3 Motifs and BH3-Mediated Interactions
Here, we aim to provide an updated overview of the structural features characterizing BH3s and BH3-mediated interactions (with a focus on human proteins)
[50]
Determinants of BH3 binding specificity for Mcl-1 vs. Bcl-xL - NIH
The dissociation constant for binding of Bim-BH3 to any pro-survival protein was fixed at a Kd value of 1 nM, because tighter binding could not be ...
[51]
Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables ...
Feb 20, 2020 · Bcl-x L inhibits apoptosis as a higher-order complex that binds multiple BH3 proteins. Allosteric regulation of this complex by the BH3 sensitizer Bad confers ...
[52]
Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis ... - NIH
Unexpectedly, the regulation of ER Ca2+ dynamics is a principal avenue whereby BCL-2 phosphorylation alters susceptibility to apoptosis. Keywords: apoptosis, ...Missing: envelope | Show results with:envelope
[53]
Dual Role of JNK1-Mediated Phosphorylation of Bcl-2 in Autophagy ...
Aug 6, 2025 · The lower degree of BcL2 phosphorylation resulted in autophagy induction, while more extensive BCL2 phosphorylation reduced its affinity to BAX, ...
[54]
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin ...
The formation of a ternary complex between Bcl-2, ARTS and XIAP enables Bcl-2 ubiquitylation by XIAP and its subsequent degradation by the proteasome [36]. The ...2. The Ubiquitin Proteasome... · 3.1. P53 · 4.1. Proteasome Inhibitors
[55]
Bcl-2 Homodimerization Involves Two Distinct Binding Surfaces, a ...
The two binding surfaces are on separate faces of the three-dimensional structure, explaining the formation of Bcl-2 homodimers, homo-oligomers, and Bcl-2/Bax ...
[56]
Bax dimerizes via a symmetric BH3:groove interface during apoptosis
Oct 21, 2011 · Reciprocity of the BH3:groove interaction generates symmetric dimers that can be linked via a second interface between α6–helices to form the ...
[57]
Bcl-2 Overexpression Leads to Increases in Suppressor of Cytokine ...
Eighty-five percent of follicular lymphomas harbor t(14;18)(q32;q21 ... Substantial evidence supports the hypothesis that t(14;18) and Bcl-2 ...Abstract · Introduction · Results · Discussion
[58]
BCL2-Rearrangement Negative Follicular Lymphomas
In 85% - 90% of FL cases, there is a pathogenic t(14;18)(q32;q21)/IGH::BCL2 rearrangement (BCL2-R) which results in the overexpression of BCL2. Co-expression of ...
[59]
Expression of bcl-2--protein in small cell lung cancer - PubMed
One-hundred twenty-five cases (76%) demonstrated expression of bcl-2. There was no difference in serum LDH levels and proliferative activity between the two ...
[60]
High prevalence of bcl-2 oncoprotein expression in small cell lung ...
Bcl-2 staining was seen in nine of 13 small cell lung cancers (69%), while only 18 out of 69 non-small cell lung cancers (26%) expressed bcl-2 oncoprotein, ...Missing: percentage | Show results with:percentage<|separator|>
[61]
Studies on p53, BAX and Bcl-2 protein expression and microsatellite ...
Apr 10, 2007 · Median follow-up was 84.5 months. We found that BAX, Bcl-2 and p53 protein expressions were high or positive in 59, 70 and 50% of 188 cases, ...
[62]
Bcl-2 Inhibition to Overcome Resistance to Chemo - PubMed Central
Bcl-2 over-expression has been widely described in different types of malignancies and is related to tumor formation, progression, therapy resistance and poorer ...
[63]
Targeting BCL-2 regulated apoptosis in cancer | Open Biology
May 16, 2018 · When unbalanced, the BCL-2 family can act as a barrier to apoptosis and facilitate tumour development and resistance to cancer therapy. Here we ...Targeting Bcl-2 Regulated... · 2. The Bcl-2 Family · 6. Inhibiting Bcl-2 Proteins...
[64]
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 ...
Jul 9, 2019 · Earlier studies reported that 5–15% of DLBCL harbored MYC, BLC2, and/or BCL6 translocations and were called “double-hit” lymphoma (DHL) or ...
[65]
MYC‐associated and double‐hit lymphomas: A review of ...
Jul 24, 2014 · The co-presence of MYC and BCL2, termed double hit lymphomas, occurs in up to one-third of diffuse large B-cell lymphomas via ...
[66]
Differences in clinical importance of Bcl-2 in breast cancer according ...
Oct 15, 2015 · Bcl-2 expression is an independent poor prognostic factor in patients with hormone receptor-negative or triple-negative breast cancers, especially in the ...
[67]
Different Prognostic Significance of Bcl-2 Based on Cancer ...
In a multivariate analysis, bcl-2 expression remained a significant predictor of recurrence in patients with the triple-negative subtype (hazard ratio, 3.26; 95 ...
[68]
Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
This review aims to summarize current data from completed clinical trials that used Bcl-2 protein family inhibitors as monotherapy or in combination with other ...
[69]
High levels of bcl-2 protein in circulating T lymphocytes ... - PubMed
Results: In SLE patients, a significant proportion of T cells expressed increased amounts of bcl-2 protein. By fluorescence-activated cell sorter analysis, bcl- ...Missing: elevated | Show results with:elevated
[70]
The bcl-2 proto-oncogene is overexpressed in systemic lupus ...
This raises the possibility that the increased expression of bcl-2 seen in lymphoid cells from SLE patients may be of intrinsic genetic origin rather than ...Missing: elevated | Show results with:elevated
[71]
Evaluation of the interaction between anti-apoptotic Bcl-2 protein ...
The study revealed that the expression of anti-apoptotic Bcl-2 and Bcl-2-L2 was significantly higher in SLE patients than control subjects.Missing: elevated cells
[72]
Critical roles of Bim in T cell activation and T cell–mediated ... - JCI
May 1, 2009 · Bim, the B cell lymphoma 2–interacting (Bcl2-interacting) mediator, maintains immunological tolerance by deleting autoreactive lymphocytes ...Missing: imbalance | Show results with:imbalance
[73]
BIM Deficiency Protects NOD Mice From Diabetes by Diverting ...
May 6, 2015 · The importance of Tregs and thymic deletion in preventing autoimmunity is illustrated in immunodysregulation polyendocrinopathy enteropathy X- ...
[74]
Programmed Cell Death of Dendritic Cells in Immune Regulation
Increased survival of DCs with the expression of Bcl-2 transgene has been shown to enhance antigen-specific T cell activation and antibody production (64, 65).
[75]
Bcl-2 Controls Dendritic Cell Longevity In Vivo - ResearchGate
Aug 6, 2025 · Overall, these data indicate that down-regulation of Bcl-2 controls DC longevity, which in turn directly regulates immune responses and the ...
[76]
Central role of mitochondria and p53 in Fas-mediated apoptosis of ...
We found that the mitochondrial apoptotic pathway played a central role in Fas-mediated apoptosis of RA synovial fibroblasts and that p53 was secondarily ...
[77]
Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression ...
Apoptosis of fibroblasts in the RA synovial sublining is characterized by a distinct multistep ultrastructural pattern with a detectable initial Fas antigen ...Missing: inhibitors | Show results with:inhibitors
[78]
Caspase cleavage of the amyloid precursor protein is prevented ...
Caspase cleavage of the amyloid precursor protein is prevented after overexpression of bcl-2 in a triple transgenic mouse model of Alzheimer's disease. Debra ...Missing: neuroprotection | Show results with:neuroprotection
[79]
Cortical bcl-2 protein expression and apoptotic regulation ... - PubMed
Conclusions: Contrary to our hypothesis, cortical Bcl-2 was reduced in schizophrenia. This supports the notion that schizophrenia is not a classic ...Missing: prefrontal | Show results with:prefrontal
[80]
(PDF) Apoptotic Proteins in the Temporal Cortex in Schizophrenia
Aug 6, 2025 · Levels of antiapoptotic Bcl-2 protein are low in the temporal cortex of schizophrenia patients. Bcl-2 interacts with the proapoptotic Bax ...
[81]
[PDF] Study of association between schizophrenia and functional ...
Apr 20, 2014 · Postmortem studies demonstrated the increased expression level of Bax encoding gene and high Bax/Bcl-2 proteins ratio in schizophrenia. However, ...
[82]
bcl-2 prolongs neuronal survival during hypoxia-induced apoptosis
In vivo models of hypoxic-ischemic brain injury have shown altered expression of a number of genes that are important in regulating neuronal survival.Missing: stroke knockout
[83]
Targeted Disruption of the bcl-2 Gene in Mice Exacerbates Focal ...
Bcl-2 ablation did not influence cerebral blood flow but it significantly increased infarct size and neurological deficit score at 1 day after reperfusion in a ...
[84]
The Bcl-2 homologue Buffy rescues α-synuclein-induced Parkinson ...
May 18, 2016 · The directed expression of Buffy in DA neurons provide protection and counteracts the α-synuclein-induced Parkinson disease-like phenotypes.
[85]
BCL2 Antibodies Targeted At Different Epitopes Detect Varying ...
In this study, we evaluated BCL2 staining with two new rabbit monoclonal antibodies (E17 and SP66) compared to clone 124 in DLBCL tissues. In cases with ...
[86]
BCL2 expression in DLBCL: reappraisal of immunohistochemistry ...
Jul 27, 2017 · We initially designed 4-grade BCL2 scoring criteria, from 0 to 3+, and found that ∼40% of DLBCL showed strong BCL2 expression (score 3+). The ...
[87]
A bioclinical prognostic model using MYC and BCL2 predicts ...
Feb 1, 2018 · Similarly, 3-year EFS rates were 25% vs. 41% (P=0.03) and OS rates were 37% vs. 63% (P=0.02) for BCL2+ vs. BCL2- cases, ...Results · Biomarker Analysis All... · Discussion<|control11|><|separator|>
[88]
BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large ...
Results: BCL2 protein expression has significant impact on overall survival (OS) and event-free survival (EFS) in DLBCL (OS, P = 0.009; EFS, P = 0.001) and GCB- ...
[89]
Development of a flow cytometric method for quantification of BCL‐2 ...
May 14, 2016 · We have developed a quantitative fluorescence cytometry (QFCM) method that can be used to measure BCL-2 family member proteins in cell lines and clinical ...
[90]
Measurable residual disease in chronic lymphocytic leukemia - Nature
Jun 24, 2021 · Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden.Quantifying Mrd · Mrd In Response Assessment · U-Mrd As A Potential...
[91]
Effect of Cnidium Lactone on Serum Mutant P53 and BCL-2/BAX ...
... Serum BCL-2/BAX expression levels comparison. * P<0.05, compared with ... prostate cancer model and induce prostate cancer cell apoptosis. It exhibited ...
[92]
An Immunohistochemistry Study of Tissue Bcl‐2 Expression and Its ...
Sep 29, 2008 · The mean ± SD of serum Bcl-2 was 3.2 ± 0.7 ng/mL in the control group. The mean ± SD of serum Bcl-2 was 3.6 ± 1.1 ng/mL in patient groups.
[93]
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical ...
A series of high affinity small organic molecules that inhibits the interaction of BCL2 with the apoptotic machinery, the so‐called BH3‐mimetics, have been ...
[94]
BH3-mimetics: recent developments in cancer therapy
Nov 9, 2021 · The principles of BH3-mimetics are mechanistically founded on disrupting the interaction of the pro-apoptotic BH3 domain with the hydrophobic ...
[95]
Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide)
Oblimersen sodium is an antisense oligonucleotide compound designed to specifically bind to human bcl-2 mRNA, resulting in catalytic degradation of bcl-2 mRNA.
[96]
BCL-2–Selective Inhibitors Spare Platelets | Cancer Discovery
However, BCL-XL is also a key survival factor for platelets, and BCL-XL inhibition by navitoclax leads to a rapid decrease in circulating platelets, or ...
[97]
Bcl-2 inhibition in the treatment of hematologic malignancies
Dec 3, 2023 · Increased Mcl-1 is also one of the key mechanisms of Bcl-2 inhibitor resistance. It has been shown that AML blasts in recurrent disease have ...<|separator|>
[98]
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
May 10, 2023 · Venetoclax–obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL.<|separator|>
[99]
Combining BTK inhibitors with BCL2 inhibitors for treating chronic ...
Apr 4, 2022 · The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
[100]
BCL-2 Inhibitors Market Analysis And Forecast 2025-2034
In stockThe BCL-2 inhibitors market size has grown rapidly in recent years. It will grow from $2.1 billion in 2024 to $2.46 billion in 2025 at a compound annual growth ...
[101]
Oblimersen - an overview | ScienceDirect Topics
Oblimersen binds with the first six codons of Bcl-2 mRNA open reading frame and mediates RNA cleavage by RNase H to downregulate Bcl-2 [68]. The antitumor ...Missing: percentage | Show results with:percentage
[102]
Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide ...
Oblimersen is the first oligonucleotide to demonstrate proof of principle of an antisense effect in human tumors by the documented downregulation of the target ...Missing: mechanism H percentage
[103]
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients ...
Oct 10, 2006 · The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival.
[104]
Melanoma: Interesting 'Almosts' in Targeted Therapy - Oncology Times
The trial remains negative, showing no overall survival benefit in the combination arm compared with the control arm, with a median survival of 9.0 vs 7.8 ...
[105]
FDA says Genta's Genasense not approvable - The Pharma Letter
Dec 22, 2006 · FDA says Genta's Genasense not approvable. fda, says, genta ... development for gastric cancer. 12 September 2025. Pharmaceutical.
[106]
Genta Announces Results of AGENDA Phase 3 Trial of GenasenseÂ ...
Nov 16, 2009 · The results do not show a statistically significant benefit for the co-primary endpoint of progression-free survival, nor for secondary ...
[107]
Oligonucleotide Therapeutics - PMC - PubMed Central
Further trials of oblimersen in AML are not planned. Another hematologic malignancy in which oblimersen was not successful in phase III was multiple myeloma.
[108]
Oblimersen for the treatment of patients with chronic lymphocytic ...
The most common events were pyrexia (33% of patients); fatigue (30%); cough and hypotension (20% each); and anemia, thrombocytopenia, nausea, and night sweats ( ...
[109]
Antisense therapy in malignant diseases: status quo and quo vadis?
Adverse events that were significantly greater in the oblimersen-treatment group included nausea, vomiting, neutropenia, thrombocytopenia, fever and catheter- ...
[110]
An inhibitor of Bcl-2 family proteins induces regression of solid tumours - Nature
**Summary of ABT-737 from Nature Article (https://www.nature.com/articles/nature03579):**
[111]
Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
Nov 25, 2020 · Navitoclax has been demonstrated as a single agent or in combination with other drugs to successfully ameliorate tumor progression and fibrosis development.Introduction · Role of Navitoclax on Cancer... · Navitoclax in Combination...
[112]
NCT02079740 | Trametinib and Navitoclax in Treating Patients With ...
This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax and how well they work in treating patients with solid tumors.
[113]
Pathways and mechanisms of venetoclax resistance - PMC - NIH
Potential mechanism of action of ABT-199 (venetoclax). Venetoclax binds to the BH3-binding groove of BCL-2 and displaces Bim and other BH3-only proteins ...Missing: debulking | Show results with:debulking
[114]
Venetoclax in Patients with Previously Treated Chronic Lymphocytic ...
Venetoclax is the first selective BCL2 inhibitor and the first BH3 mimetic drug to receive FDA approval. Consistent with the central role BCL2 plays in ...Missing: specificity Ki values
[115]
The MURANO study: final analysis and retreatment/crossover ...
Jun 5, 2025 · At the final data cut (3 August 2022), the median PFS with VenR was 54.7 months vs 17.0 months with BR. The 7-year PFS with VenR was 23.0%.
[116]
Long-term follow-up of venetoclax monotherapy in previously ... - NIH
BCL2 G101V mutations were not detected in patients who completed venetoclax therapy, and retreatment with venetoclax induced deep responses. Visual Abstract.
[117]
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a ...
Although venetoclax has shown significant efficacy, particularly in CLL patients, and encouraging activity against multiple myeloma (24) (MM) and estrogen ...
[118]
Potential of BGB-11417, a BCL2 inhibitor, in hematological ...
Jan 26, 2024 · Sonrotoclax (BGB-11417) is a remarkably potent and selective BCL2 inhibitor, capable of inhibiting both wild-type and G101V-mutated BCL2 in 'in vitro' studies.
[119]
Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax ...
May 2, 2024 · Sonrotoclax is a potent and selective BCL2 inhibitor that is also effective in venetoclax-resistant BCL2 mutants both in vitro and in vivo.
[120]
Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax ...
In this study, we discovered that sonrotoclax, a potent and selective BCL2 inhibitor, demonstrates stronger cytotoxic activity in various hematologic cancer ...
[121]
https://pubmed.ncbi.nlm.nih.gov/38211332/
[122]
[PDF] Sonrotoclax monotherapy for treatment of patients with relapsed ...
Jun 12, 2025 · Sonrotoclax Monotherapy for Treatment of Patients With Relapsed/Refractory CLL: Data From an Ongoing ... • BGB-11417-101 (NCT04277637) is an ...
[123]
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed ...
Jun 17, 2024 · The combination therapy showed a 97% overall response rate and a 57% complete response rate in relapsed/refractory CLL/SLL patients. · No dose- ...
[124]
Paper: CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional ...
Presented here is the design of a phase 3 trial aimed at comparing the efficacy of sonrotoclax + zanubrutinib vs venetoclax + obinutuzumab in patients with TN ...
[125]
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with ... - PubMed
Dec 15, 2022 · Lisaftoclax is a novel, orally bioavailable BH3 mimetic BCL-2-selective inhibitor with considerable potential for the treatment of certain hematologic ...
[126]
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust ...
Specifically, an isoform 2 construct of human BCL-2 with an N-terminal 6xHis tag (a polyhistidine tag) was used. Human BCL-xL constructs with internal ...
[127]
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic ...
The recommended phase 2 dose of lisaftoclax monotherapy for patients with CLL/SLL is 600 mg. Tumor lysis syndrome. There was no evidence of clinical or ...
[128]
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax ...
Lisaftoclax combined with alrizomadlin overcomes BCL-2 gene mutation-conferred drug resistance, including primary ex vivo samples from patients with AML who ...
[129]
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax ...
Jul 10, 2025 · In April 2025, supported by its groundbreaking efficacy and safety data in Chinese patients with CLL/SLL, lisaftoclax was included in the 2025 ...
[130]
Lisaftoclax approved by China's NMPA for adult patients with CLL/SLL
On July 10, 2025, China's NMPA granted approval for lisaftoclax (APG-2575) for the treatment of adult patients with CLL/SLL who have previously received ≥1 ...
[131]
Lisaftoclax Wins Chinese Approval in Pretreated Chronic ... - OncLive
Jul 11, 2025 · Lisaftoclax is the first BCL-2 inhibitor approved in China for CLL/SLL, demonstrating significant efficacy and a favorable safety profile in ...
[132]
Phase 1b/2 study of lisaftoclax (APG-2575) combined with ...
May 28, 2025 · LISA at different dose regimens combined with AZA provides promising treatment options for pts with HR-MDS or AML. No DLTs occurred. The MTD was not reached.
[133]
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which ...
May 22, 2025 · Lisaftoclax is a novel investigational oral selective Bcl-2 inhibitor that has shown enhanced treatment response when combined with azacitidine in prior ...
[134]
Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor ...
Jun 2, 2025 · Lisaftoclax is an investigational, orally active, small-molecule Bcl-2 inhibitor that has shown enhanced treatment responses in AML and MDS when ...
[135]
Global Phase 3 Trial of Lisaftoclax Cleared for Higher-Risk MDS
Aug 18, 2025 · The FDA and EMA have cleared a global registrational phase 3 study for lisaftoclax (APG-2575), a novel BCL-2 inhibitor.
[136]
Ascentage Pharma Announces Global Registrational Phase III Study ...
Aug 17, 2025 · GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in ...
[137]
NCT06319456 | A Global Study of Lisaftoclax (APG-2575 ...
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in ...Missing: NCT05673426 | Show results with:NCT05673426
[138]
Preliminary safety and efficacy data of ICP-248, a novel BCL2 ...
May 28, 2025 · The only approved BCL2 inhibitor, Venetoclax, has been approved for the treatment of chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) ...
[139]
[PDF] generation BCL2 inhibitor, in patients with B-c
Results: As of May 16, 2025, 44 patients with B-NHL had been enrolled in the dose- escalation cohort and received BGB-21447 at target doses ranging from 10 mg ...<|control11|><|separator|>
[140]
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a ...
We have developed a strategy to selectively target BCL-xL in tumors, while sparing platelets, by utilizing proteolysis-targeting chimeras (PROTACs).
[141]
Preclinical assessment of combined BCL-2 and MCL-1 inhibition in ...
Dual inhibition of BCL-2 and MCL-1 in neuroblastoma cells showed highly efficacious and synergistic responses in vitro, but only led to mild additive effects ...